Prospective, non-interventional study on the real-world use of certoparin in daily practice--the PROMEMBER study.

Abstract

BACKGROUND:

We aimed to verify safety and effectiveness of certoparin real-world use and to identify predictors of thromboembolic events or bleeding.

METHODS:

This was a non-interventional study documenting patients at hospital- or office-based physicians.

RESULTS:

Patients' (n = 1407) mean age was 53.7 ± 16.1 years. Reason for certoparin use was prophylaxis of venous thromboembolism in 1331 (94.6%) patients and treatment in 76 (5.4%) patients. In only 11.4% of those receiving prophylaxis and 13.2% of those receiving treatment dosing, duration and schedule of certoparin were within label. There were 2 patients with deep venous thrombosis ([DVT], no pulmonary embolism [PE]), and 51 patients (3.8%) with minor (nonmajor) bleeding complications in patients receiving prophylaxis. Two patients treated with certoparin had recurrent DVT and one had PE (one patient with minor bleeding).

CONCLUSIONS:

Certoparin is very effective in real world. This also applies to patients in whom clinical decision making leads to an alteration of recommended application.

• Authors: Michael Spannagl, Nima Melzer, Peter Bramlage, Cornelia Englert, Ralf Eisele
• Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (Clin Appl Thromb Hemost) 2013 Jan-Feb Vol. 19 Issue 1 Pg. 86-91 ISSN: 1938-2723 [Electronic] United States
• PMID: 22696592 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Anticoagulants
• Heparin, Low-Molecular-Weight
• certoparin

Topics

• Aged
• Anticoagulants (administration & dosage, adverse effects)
• Female
• Hemorrhage (chemically induced)
• Heparin, Low-Molecular-Weight (administration & dosage, adverse effects)
• Humans
• Male
• Middle Aged
• Prospective Studies
• Thromboembolism (prevention & control)
• Venous Thrombosis (drug therapy)